HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. reduced its stake in HUTCHMED (China) Limited (NASDAQ:HCM) by 38.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,109 shares of the company’s stock after selling 18,615 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in HUTCHMED were worth $434,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Summit Trail Advisors LLC raised its holdings in shares of HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock valued at $189,000 after buying an additional 1,647 shares during the last quarter. Crossmark Global Holdings Inc. lifted its position in HUTCHMED by 10.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company’s stock worth $268,000 after purchasing an additional 1,799 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in HUTCHMED in the third quarter worth approximately $35,000. State Street Corp lifted its position in HUTCHMED by 0.9% in the third quarter. State Street Corp now owns 349,524 shares of the company’s stock worth $6,826,000 after purchasing an additional 3,078 shares during the period. Finally, Blue Trust Inc. lifted its position in HUTCHMED by 99.9% in the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock worth $102,000 after purchasing an additional 3,532 shares during the period. 8.82% of the stock is currently owned by institutional investors and hedge funds.

HUTCHMED Price Performance

Shares of NASDAQ:HCM opened at $14.99 on Friday. The company’s fifty day moving average is $14.69 and its two-hundred day moving average is $16.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68. HUTCHMED has a 12-month low of $12.84 and a 12-month high of $21.92.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research report on Friday.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.